信立泰：SAL0140片治疗慢性肾脏病获批临床试验

Core Viewpoint - The company, Xinlitai, has received approval from the National Medical Products Administration to conduct clinical trials for its innovative small molecule drug SAL0140 tablets aimed at treating chronic kidney disease (CKD) [1] Company Summary - Xinlitai announced on December 3 that it has obtained the clinical trial approval notice for SAL0140 tablets [1]